National Drug Plan For Sri Lanka?

4 June 1995

A national drug policy for Sri Lanka has been proposed by the national Drug Evaluation Committee, following requests by the Sri Lanka Pharmaceutical Traders Association to allow a free flow of medicines which have been registered with the Committee.

Currently, all drug companies are required to register new imports with the Committee, which the traders say causes undue delays.

Meantime, the Health Ministry has voiced concern at the high prices charged for medicines, and has warned the pharmaceutical industry that it has an obligation to provide affordable drugs and to refrain from charging exorbitant prices. Affordable alternatives are available for most of the expensive drugs sold in the private sector, says the Ministry, adding that: "for every expensive product with a commercial brand name, there is almost always an affordable product in its generic name."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight